Equine sarcoids: Bovine Papillomavirus type 1 transformed fibroblasts are sensitive to cisplatin and UVB induced apoptosis and show aberrant expression of p53 [PDF]
, 2012 Bovine papillomavirus type 1 infects not only cattle but also equids and is a causative factor in the pathogenesis of commonly occurring equine sarcoid tumours.
Finlay, M. +14 more
core +1 more source
Frontiers in Pharmacology, 2017 Resistance to platinum-based chemotherapy is one of the most important reasons for treatment failure in advanced non-small cell lung cancer, but the underlying mechanism is extremely complex and unclear.
Aman Wang +7 more
doaj +1 more source
Interactions of DNA with a new Platinum(IV) Azide Dipyridine complex activated by UVA and visible light : relationship to toxicity in tumor cells [PDF]
, 2012 The Pt IV diazido complex trans,trans,trans-[Pt(N 3) 2(OH) 2(pyridine) 2] (1) is unreactive in the dark but is cytotoxic when photoactivated by UVA and visible light.
Sadler, P. J. +15 more
core +1 more source
Characterization of a Cisplatin-resistant HeLa subline and mechanisms of cisplatin-resistance.
Journal of Japan Society for Oral Tumors, 1990 ヒト口腔領域由来腫瘍細胞, UEDA, NAKATA, KANETSUKI, HSG, HSY, 子宮頸部由来HeLa, 外陰部由来A431の7種の培養細胞を用いてシスプラチンに対する感受性を検索した。腺癌細胞は扁平上皮癌細胞に比べてシスプラチンに対して高い感受性を示し, 唾液腺腺癌に化学療法が有用であると示唆された。また, 一方扁平上皮癌細胞は自然耐性を示した。シスプラチンに感受性の高い細胞は高い細胞内シスプラチン濃度を示し, シスプラチンの取り込みは殺細胞効果を反映すると考えられた。シスプラチン耐性のメカニズムを解明するためにHeLa細胞を用いてシスプラチン耐性細胞を分離した (HeLaDDP) 。同細胞はシスプラチン非存在下17ケ月間継代培養した後も約4.3倍の安定した耐性を発現していた ...
Furue, Miho +2 more
openaire +2 more sources
Use of top-down and bottom-up fourier transform ion cyclotron resonance mass spectrometry for mapping calmodulin sites modified by platinum anticancer drugs [PDF]
, 2011 Calmodulin (CaM) is a highly conserved, ubiquitous, calcium-binding protein; it binds to and regulates many different protein targets, thereby functioning as a calcium sensor and signal transducer.
Lin, Tzu-Yung +17 more
core +1 more source
Frontiers in Cell and Developmental Biology, 2020 Cisplatin [cis-diamminedichloroplatinum (II)] is a platinum-based anticancer drug widely used for the treatment of various cancers. It forms interstrand and intrastrand cross-linking with DNA and block DNA replication, resulting in apoptosis.
Takahiro Shimizu +2 more
doaj +1 more source
ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair [PDF]
, 2008 Background: The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum-drug resistance. Resistance was not associated with increased cellular glutathione or decreased accumulation of platinum, rather the resistant cell lines have a cell
Davey, Ross, Stordal, Britta
core +1 more source
CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma. [PDF]
PLoS ONE, 2014 Osteosarcoma (OS) is the most common form of malignant bone tumor and is an aggressive malignant neoplasm exhibiting osteoblastic differentiation. Cisplatin is one of the most efficacious antitumor drugs for osteosarcoma patients.
Hsiao-Chi Tsai +3 more
doaj +1 more source
Protein flexibility is key to cisplatin crosslinking in calmodulin [PDF]
, 2012 Chemical crosslinking in combination with Fourier transform ion cyclotron resonance mass spectrometry (FTICR MS) has significant potential for studying protein structures and proteinprotein interactions.
Römer, Rudolf A. +6 more
core +1 more source
Journal of Experimental & Clinical Cancer Research, 2019 Background Cisplatin is the first-line chemotherapy used against most upper aerodigestive tract carcinomas. In head and neck cancer, sensitivity to cisplatin remains the key issue in treatment response and outcome. Genetic heterogeneity and aberrant gene
Wei-Min Chang +5 more
doaj +1 more source